OSS-128167

OSS-128167
Clinical data
Drug class	Sirtuin-6 (SIRT6) inhibitor
Identifiers
	IUPAC name 5-[[3-(furan-2-carbonylamino)benzoyl]amino]-2-hydroxybenzoic acid;
CAS Number	887686-02-4;
PubChem CID	6496840;
ChemSpider	4997276;
ChEMBL	ChEMBL1588664;
Chemical and physical data
Formula	C19H14N2O6
Molar mass	366.329 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=CC(=CC(=C1)NC(=O)C2=CC=CO2)C(=O)NC3=CC(=C(C=C3)O)C(=O)O;
	InChI InChI=1S/C19H14N2O6/c22-15-7-6-13(10-14(15)19(25)26)20-17(23)11-3-1-4-12(9-11)21-18(24)16-5-2-8-27-16/h1-10,22H,(H,20,23)(H,21,24)(H,25,26); Key:HTJWLEGCECXGSQ-UHFFFAOYSA-N;

OSS-128167 is a drug which acts as a sirtuin-6 (SIRT6) inhibitor. It has pro-inflammatory effects and accelerates cellular aging; however, it shows anti-viral and anti-cancer properties which are useful in research, and has also demonstrated potential medical applications for SIRT6 inhibitors such as in the treatment of some forms of asthma.^[1]^[2]^[3]^[4]^[5]

References

^ Jiang H, Cheng ST, Ren JH, Ren F, Yu HB, Wang Q, et al. (2019). "SIRT6 Inhibitor, OSS_128167 Restricts Hepatitis B Virus Transcription and Replication Through Targeting Transcription Factor Peroxisome Proliferator-Activated Receptors α". Frontiers in Pharmacology. 10 1270. doi:10.3389/fphar.2019.01270. PMC 6823301. PMID 31708789.
^ Yang J, Li Y, Zhang Y, Fang X, Chen N, Zhou X, et al. (July 2020). "Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling". Journal of Experimental & Clinical Cancer Research. 39 (1) 142. doi:10.1186/s13046-020-01623-w. PMC 7382040. PMID 32711549.
^ Huang Y, Zhang J, Xu D, Peng Y, Jin Y, Zhang L (May 2021). "SIRT6‑specific inhibitor OSS‑128167 exacerbates diabetic cardiomyopathy by aggravating inflammation and oxidative stress". Molecular Medicine Reports. 23 (5) 367. doi:10.3892/mmr.2021.12006. PMC 7986000. PMID 33760202.
^ Zhou H, Liu S, Zhang N, Fang K, Zong J, An Y, et al. (December 2022). "Downregulation of Sirt6 by CD38 promotes cell senescence and aging". Aging. 14 (23): 9730–9757. doi:10.18632/aging.204425. PMC 9792202. PMID 36490326.
^ Quan J, Wen X, Su G, Zhong Y, Huang T, Xiong Z, et al. (December 2023). "Epithelial SIRT6 governs IL-17A pathogenicity and drives allergic airway inflammation and remodeling". Nature Communications. 14 (1) 8525. Bibcode:2023NatCo..14.8525Q. doi:10.1038/s41467-023-44179-x. PMC 10746710. PMID 38135684.

[1] Jiang H, Cheng ST, Ren JH, Ren F, Yu HB, Wang Q, et al. (2019). "SIRT6 Inhibitor, OSS_128167 Restricts Hepatitis B Virus Transcription and Replication Through Targeting Transcription Factor Peroxisome Proliferator-Activated Receptors α". Frontiers in Pharmacology. 10 1270. doi:10.3389/fphar.2019.01270. PMC 6823301. PMID 31708789.

[2] Yang J, Li Y, Zhang Y, Fang X, Chen N, Zhou X, et al. (July 2020). "Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling". Journal of Experimental & Clinical Cancer Research. 39 (1) 142. doi:10.1186/s13046-020-01623-w. PMC 7382040. PMID 32711549.

[3] Huang Y, Zhang J, Xu D, Peng Y, Jin Y, Zhang L (May 2021). "SIRT6‑specific inhibitor OSS‑128167 exacerbates diabetic cardiomyopathy by aggravating inflammation and oxidative stress". Molecular Medicine Reports. 23 (5) 367. doi:10.3892/mmr.2021.12006. PMC 7986000. PMID 33760202.

[4] Zhou H, Liu S, Zhang N, Fang K, Zong J, An Y, et al. (December 2022). "Downregulation of Sirt6 by CD38 promotes cell senescence and aging". Aging. 14 (23): 9730–9757. doi:10.18632/aging.204425. PMC 9792202. PMID 36490326.

[5] Quan J, Wen X, Su G, Zhong Y, Huang T, Xiong Z, et al. (December 2023). "Epithelial SIRT6 governs IL-17A pathogenicity and drives allergic airway inflammation and remodeling". Nature Communications. 14 (1) 8525. Bibcode:2023NatCo..14.8525Q. doi:10.1038/s41467-023-44179-x. PMC 10746710. PMID 38135684.

[1]

[2]

[3]

[4]

[5]